-
Cancer Genetics offers the FDA-approved DAKO PD-L1 IHC 22C3 pharmDx companion diagnostic test for KEYTRUDA®
The FDA approved PD-L1 (IHC) 22C3 pharmDx companion diagnostic test for KEYTRUDA® (pembrolizumab) is now available at CGI to assess PD-L1 expression in Non-Small Cell Lung Cancer
